Nih-sponsored trial finds eylea® (aflibercept) injection reduced vision-threatening complications by 68% after two years in diabetic retinopathy patients

Tarrytown, n.y., march 30, 2021 /prnewswire/ -- protocol w trial data confirm results from panorama trial showing eylea significantly reduced vision-threatening complications and improved anatomic measures of diabetic retinopathy    although patients' overall vision was similar in the eylea and sham groups at two years in protocol w, a new analysis from panorama shows that delaying eylea treatment (sham group) was associated with prolonged periods of vision loss two diabetic retinopathy trials (protocol w and panorama) have now shown the benefit of eylea every 16 weeks following an initial dosing period; regeneron to discuss 16-week dosing interval with u.s. fda regeneron pharmaceuticals, inc. (nasdaq: regn) today announced jama ophthalmology has published initial results from the national institutes of health-sponsored protocol w trial assessing eylea® (aflibercept) injection in patients with moderate to severe non-proliferative diabetic retinopathy (npdr), without center-involved diabetic macular edema (ci-dme).
REGN Ratings Summary
REGN Quant Ranking